Literature DB >> 9517428

Endogenous nitric oxide facilitates striatal dopamine and glutamate efflux in vivo: role of ionotropic glutamate receptor-dependent mechanisms.

A R West, M P Galloway.   

Abstract

We have investigated the influence of the nitric oxide synthase (NOS) substrate, NG-hydroxy-L-arginine (H-ARG) on dopamine (DA) and glutamate (GLU) efflux in vivo using concentric microdialysis probes implanted in the anterior-medial striatum of chloral hydrate-anesthetized rats. Intrastriatal infusion of H-ARG (100 microM, 200 microM, or 1 mM for 120 min) increased DA efflux in a dose-dependent fashion. The facilitatory effect of H-ARG (1 mM) on DA efflux was abolished following pretreatment (80 min) with the constitutive NOS inhibitor 7-nitroindazole (7-NI, 10 microM) but unaffected by L-NG(1-iminoethyl) lysine (100 microM) infusion. As both H-ARG (1 mM) and the NO-generator (+/-)-S-nitroso-N-acetylpenicillamine (1 mM) were observed to increase GLU efflux concurrently with the effect on DA efflux, we evaluated the potential intermediary role of GLU in NO-facilitated DA efflux using ionotropic GLU receptor antagonists. Local infusion of dizocilpine maleate (10 microM) or (+/-)-2-amino-3-[3-(carboxymethoxy)-5-methyl-isoxazol-4-yl] propionic acid (100 microM), attenuated the H-ARG (1 mM)-induced elevation of extracellular DA levels. Conversely, similar treatment with the kainate receptor antagonist d-gamma-glutamyl-aminomethanesulfonic acid did not alter H-ARG-induced DA efflux. To evaluate the regulatory influence of striatal NO on NMDA receptor activation, NMDA (100 microM) was co-perfused with either H-ARG (2 mM) or 7-NI (10 microM). While co-perfusion with 7-NI potentiated NMDA-induced DA efflux, similar treatment with H-ARG (2 mM) abolished the effect. These results demonstrate that endogenous NO production, stimulated via H-ARG-dependent activation of type 1 NOS, enhances striatal DA efflux via an increase in glutamatergic tone on ionotropic GLU-receptors. At higher levels of NOS activation (following H-ARG (2 mM) or NMDA infusion), NO may block glutamatergic neurotransmission via inhibition of NMDA receptor function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9517428     DOI: 10.1016/s0028-3908(97)00148-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  19 in total

1.  Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis.

Authors:  Anthony R West; Anthony A Grace
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

2.  Dopamine D2 receptor-dependent modulation of striatal NO synthase activity.

Authors:  Stephen Sammut; Kristina E Bray; Anthony R West
Journal:  Psychopharmacology (Berl)       Date:  2007-01-06       Impact factor: 4.530

3.  Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.

Authors:  Elaine Del-Bel; Fernando Eduardo Padovan-Neto; Raphael Escorsim Szawka; Célia Aparecida da-Silva; Rita Raisman-Vozari; Janete Anselmo-Franci; Angélica Caroline Romano-Dutra; Francisco Silveira Guimaraes
Journal:  Neurotox Res       Date:  2013-06-27       Impact factor: 3.911

4.  Signaling Mechanisms in the Nitric Oxide Donor- and Amphetamine-Induced Dopamine Release in Mesencephalic Primary Cultured Neurons.

Authors:  Cristiane Salum; Fanny Schmidt; Patrick P Michel; Elaine Del-Bel; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2015-09-21       Impact factor: 3.911

5.  Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.

Authors:  Fernando E Padovan-Neto; Stephen Sammut; Shreaya Chakroborty; Alexander M Dec; Sarah Threlfell; Peter W Campbell; Vishnu Mudrakola; John F Harms; Christopher J Schmidt; Anthony R West
Journal:  J Neurosci       Date:  2015-04-08       Impact factor: 6.167

6.  Expression and activity of nitric oxide synthase isoforms in methamphetamine-induced striatal dopamine toxicity.

Authors:  Danielle M Friend; Jong H Son; Kristen A Keefe; Ashley N Fricks-Gleason
Journal:  J Pharmacol Exp Ther       Date:  2012-12-10       Impact factor: 4.030

7.  Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.

Authors:  M Lazzarini; C Salum; E A Del Bel
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

8.  Role of nitric oxide in amphetamine-induced sensitization of schedule-induced polydipsic rats.

Authors:  Yia-Ping Liu; Che-Se Tung; Pai-Jone Lin; Fang-Jung Wan
Journal:  Psychopharmacology (Berl)       Date:  2011-05-28       Impact factor: 4.530

9.  A study on the role of nitric oxide and iron in 3-morpholino-sydnonimine-induced increases in dopamine release in the striatum of freely moving rats.

Authors:  P A Serra; G Rocchitta; G Esposito; M R Delogu; R Migheli; E Miele; M S Desole; M Miele
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

10.  Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivo.

Authors:  Stephen Sammut; Sarah Threlfell; Anthony R West
Journal:  Neuropharmacology       Date:  2009-12-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.